Figure 7 from Dynamic Tracking of Tumor Microenvironment Modulation Using Kaede Photoconvertible Transgenic Mice Unveils New Biological Properties of Viral Immunotherapy

<p>Tumor growth was better controlled when CAN-2409 + prodrug treatment was combined with anti–CTLA-4 antibody therapy compared with CAN-2409 + prodrug alone. <b>A,</b> MC38 tumor–bearing mice were treated with or without CAN-2409 i.t. at day 10, followed by 4 days of i.p. administration of prodrug. Anti–CTLA-4 or isotype control were treated i.p. on day 10, 13, and 16. Tumor growth was monitored, and tumors were collected on day 17. <b>B,</b> Tumor weight quantification (left) and tumor growth inhibition rate (right) at study endpoint. Quantification of CD3⁺ cells (<b>C</b>), CD8⁺ T cells (<b>D</b>), CD4⁺ T cell (<b>E</b>) and Treg (<b>F</b>) by flow cytometry. <b>G</b> and <b>H,</b> Characterization of TAA-specific CD8⁺ T cells for PD1⁺ (<b>G</b>), GZB⁺ (<b>H</b>), GZB⁺CX3CR1⁺ (<b>I</b>) and Ki67⁺ (<b>J</b>). <b>K,</b> MC38tumor–bearing mice were treated with or without CAN-2409 i.t. at day 8, followed by 3 days of i.p. administration of prodrug. Anti–CTLA-4 or isotype control was treated i.p. on day 8, 11, and 14. Tumor growth was monitored, and tumors were collected on day 18. Tumor growth inhibition after treatment was calculated. Quantification of Treg (<b>L</b>) and CX3CR1^-Ki67⁺ CD8⁺ T cells (<b>M</b>) in tumor dLNs. <i>N</i> = 5–6 mice per group. One-way ANOVA with Tukey correction, *, <i>P</i> < 0.05; **, <i>P</i> < 0.01; ***, <i>P</i> < 0.001; ****, <i>P</i> < 0.0001.</p>